X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2436) 2436
humans (2328) 2328
life sciences & biomedicine (2246) 2246
male (1554) 1554
oligopeptides - therapeutic use (1201) 1201
female (1177) 1177
animals (1087) 1087
oligopeptides - adverse effects (1064) 1064
oligopeptides - pharmacology (900) 900
middle aged (888) 888
adult (757) 757
oligopeptides - administration & dosage (757) 757
pharmacology & pharmacy (524) 524
aged (521) 521
treatment outcome (494) 494
drug therapy, combination (456) 456
mice (451) 451
atazanavir sulfate (427) 427
hepatitis c, chronic - drug therapy (403) 403
antiviral agents - therapeutic use (384) 384
hiv infections - drug therapy (372) 372
oligopeptides - chemistry (356) 356
rats (339) 339
infectious diseases (310) 310
oncology (307) 307
analysis (286) 286
pyridines - adverse effects (284) 284
proline - analogs & derivatives (279) 279
antiviral agents - adverse effects (278) 278
research (273) 273
hepatitis c (262) 262
dose-response relationship, drug (261) 261
oligopeptides - pharmacokinetics (259) 259
gastroenterology & hepatology (258) 258
ribavirin - therapeutic use (256) 256
peptides (252) 252
care and treatment (237) 237
drug therapy (237) 237
pyridines - therapeutic use (235) 235
health aspects (229) 229
hepacivirus - genetics (225) 225
oligopeptides (225) 225
interferon-alpha - therapeutic use (221) 221
immunology (218) 218
abridged index medicus (214) 214
hepatitis c virus (210) 210
disease models, animal (200) 200
oligopeptides - metabolism (200) 200
time factors (197) 197
polyethylene glycols - therapeutic use (192) 192
proline - therapeutic use (191) 191
telaprevir (189) 189
biochemistry & molecular biology (188) 188
genotype (188) 188
protease inhibitors (188) 188
drug interactions (180) 180
multiple myeloma - drug therapy (174) 174
hiv protease inhibitors - adverse effects (171) 171
pyridines - administration & dosage (170) 170
hepacivirus - drug effects (167) 167
viral load (161) 161
young adult (161) 161
cancer (159) 159
hematology (157) 157
anti-hiv agents - adverse effects (156) 156
cell line, tumor (155) 155
drug administration schedule (151) 151
antiviral agents (150) 150
hepatitis c - drug therapy (149) 149
recombinant proteins - therapeutic use (149) 149
hiv (148) 148
rats, sprague-dawley (147) 147
adolescent (145) 145
medicine & public health (145) 145
virology (144) 144
science & technology - other topics (142) 142
hiv protease inhibitors - therapeutic use (141) 141
neurosciences & neurology (141) 141
medicine (140) 140
antiviral agents - administration & dosage (139) 139
anti-hiv agents - therapeutic use (137) 137
neurosciences (137) 137
cells, cultured (131) 131
ribavirin (131) 131
aged, 80 and over (130) 130
proteases (130) 130
proteins (130) 130
antineoplastic agents - therapeutic use (129) 129
hepatitis c, chronic - virology (129) 129
atazanavir (128) 128
protease inhibitors - therapeutic use (128) 128
clinical trials as topic (127) 127
risk factors (127) 127
endocrinology & metabolism (126) 126
multiple myeloma (125) 125
clinical trials (124) 124
amino acid sequence (123) 123
antineoplastic agents - adverse effects (123) 123
microbiology (122) 122
cell biology (121) 121
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3031) 3031
German (44) 44
Spanish (35) 35
Russian (28) 28
Japanese (21) 21
French (16) 16
Chinese (7) 7
Portuguese (5) 5
Danish (4) 4
Hungarian (4) 4
Polish (2) 2
Croatian (1) 1
Dutch (1) 1
Finnish (1) 1
Hebrew (1) 1
Italian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical journal of the American Society of Nephrology, ISSN 1555-9041, 01/2017, Volume 12, Issue 1, pp. 176 - 189
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 59, Issue 3, pp. 434 - 441
Journal Article
Journal of acquired immune deficiency syndromes (1999), ISSN 1525-4135, 03/2010, Volume 53, Issue 3, pp. 323 - 332
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2011, Volume 364, Issue 25, pp. 2417 - 2428
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 6, pp. 2047 - 2055
Journal Article
The Journal of infectious diseases, ISSN 1537-6613, 06/2011, Volume 203, Issue 12, pp. 1791 - 1801
Background. Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV... 
HIV/AIDS | Percentage change | RNA | Spine | Bones | Bone density | Arm | Hip | Bone fractures | HIV 1 | Arts | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Fractures, Bone - epidemiology | Male | Oligopeptides - adverse effects | Viral Load | Lamivudine - adverse effects | Tenofovir | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | Osteoporosis - chemically induced | Anti-HIV Agents - adverse effects | Risk Factors | Organophosphonates - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Absorptiometry, Photon | Bone Density - drug effects | HIV Infections - complications | Intention to Treat Analysis | HIV Infections - drug therapy | Fractures, Bone - chemically induced | Deoxycytidine - analogs & derivatives | Drug Combinations | Usage | Care and treatment | Ritonavir | Drug utilization | Lamivudine | Efavirenz | Prevention | Abacavir | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Index Medicus | Abridged Index Medicus | Major and Brief Reports
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 05/2014, Volume 73, Issue 5, pp. 831 - 837
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 3, pp. 881 - 889.e1
Background & Aims We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in... 
Gastroenterology and Hepatology | Clinical Trial | Liver Disease | C209 | VX-950 | VX-951 | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Single-Blind Method | Hepatitis C, Chronic - metabolism | Interferon-alpha - pharmacology | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Dose-Response Relationship, Drug | RNA, Viral - genetics | Adult | Female | Drug Therapy, Combination | Polyethylene Glycols - pharmacology | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Recombinant Proteins - pharmacology | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Interferon-alpha - adverse effects | Hepatitis C, Chronic - genetics | Oligopeptides - pharmacology | RNA, Viral - drug effects | Ribavirin - pharmacology | Evaluation | Complications and side effects | Care and treatment | RNA | Interferon | Genetic aspects | Hepatitis C | Hepatitis C virus | Consulting services | Ribavirin | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
... for most of these patients, and toxic effects may limit the extent of treatment in some patients.5–7 Telaprevir, a linear peptidomimetic HCV NS3/4A serine protease inhibitor... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine |